Image

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Jun 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Jun 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market, By Cancer Type (Lung, Breast, Colorectal, Prostrate, Stomach, Cervical, Leukemia and Others), Product and Service (Kits, Software and Services and Instruments), Technologies (Panels/Targeted Sequencing and Resequencing, Whole Exome Sequencing, Whole Genome Sequencing, RNA Sequencing and Other Sequencing Technologies), Workflow (NGS Sequencing, NGS Data Analysis and NGS Pre-Sequencing), Application (Screening, Companion Diagnostics and Others), End User (Pathology Labs, Hospitals, Oncology Centers and Others), Distribution Channel (Direct Tender and Retail Sales) – Industry Trends and Forecast to 2029

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market

Market Analysis and Size

One of the most important technological developments in the biological sciences during the past 30 years is likely next-generation sequencing (NGS). Multiple genomes can now be read simultaneously in a single instrument run in less than two weeks because of the rapid advancement of next generation sequencing technology. Targeted DNA enrichment techniques enable significantly greater genome throughput at lower sample cost.

Data Bridge Market Research analyses that the next generation sequencing (NGS) in cancer diagnostic market which was USD 592.56 million in 2021, would rocket up to USD 1825.29 million by 2029, and is expected to undergo a CAGR of 15.1% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Cancer Type (Lung, Breast, Colorectal, Prostrate, Stomach, Cervical, Leukemia and Others), Product and Service (Kits, Software and Services and Instruments), Technologies (Panels/Targeted Sequencing and Resequencing, Whole Exome Sequencing, Whole Genome Sequencing, RNA Sequencing and Other Sequencing Technologies), Workflow (NGS Sequencing, NGS Data Analysis and NGS Pre-Sequencing), Application (Screening, Companion Diagnostics and Others), End User (Pathology Labs, Hospitals, Oncology Centers and Others), Distribution Channel (Direct Tender and Retail Sales)

Countries Covered

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)

Market Players Covered

Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies Inc. (U.S.), Myriad Genetics Inc. (U.S.), BGI (China), Perkin Elmer Inc. (U.S.), Foundation Medicine Inc. (U.S.), PacBio (U.S.), Oxford Nanopore Technologies plc. (U.K.), Paradigm Diagnostics Inc. (U.S.), Caris Life Sciences (Japan), Partek, Incorporated (U.S.), Eurofins Scientific (Luxembourg), Qiagen (Germany)

Market Opportunities

  • Rapidly increasing cancer cases have become a major issue all over the world
  • Government and a variety of other healthcare organisations are taking steps to combat cancer's global burden

Market Definition

High-throughput sequencing is another term for next generation sequencing, or NGS. It is a remarkable technology that uses extreme parallelization to assemble enormous DNA strands. The innovation lessens the requirement for segment cloning, a step in Sanger genome sequencing. Fast processes, exact performance, and organisational convenience even with tiny sample data are the key advantages that NGS offers over Sanger's sequencing methodology.

Next Generation Sequencing (NGS) in Cancer Diagnostic Market Dynamics

Drivers

  • Increase in cancer cases

The next generation sequencing in cancer diagnostic market is projected to be impacted significantly by improvements in personalized medicine and oncology. Rising cancer prevalence, high acceptance of sequencing-based diagnostics platforms among practicing oncologists, decrease in the cost of genetic sequencing, and increased government R&D funding are some of the reasons expected to boost market growth. On the other hand, high adoption of this technique over single-gene testing, as well as higher adoption of clinical oncology next generation sequencing technology and platforms in academia projects, will propel the next generation sequencing in cancer diagnostic market from 2022 to 2029.

  • New technological Innovations

According to the World Health Organization's (WHO) International Agency for Research on Cancer (IARC), cancer was the top cause of death worldwide in 2020, with over 10 million fatalities. In addition, 19.3 million additional cases were reported globally. New creative technologies, such as next generation sequencing, are being used to address this worldwide burden and lower mortality rates. As a result, the next generation sequencing in cancer diagnostic market is growing at a faster rate.

  • Reduction in the cost of NGS platforms

The factor aiding the market's growth is the reduction in the cost of NGS platforms. Clinical oncology next-generation sequencing approaches provide a high percentage of reads as well as low cost per read. Leading players are introducing low-cost sequencing approaches. Similarly, the worldwide next generation sequencing in cancer diagnostic market will expand over the forecast period as more people use next generation sequencing for liquid biopsy.

Opportunities

NGS deployment in a clinical setting offers a number of intriguing possibilities, therefore it is not expected that there is a great deal of interest in this area. Some of these techniques will merely replace current Sanger sequencing or PCR-based assays for genetic testing within genes associated with familial cancer syndromes or for spotting mutations in therapeutically significant genes within cancer cells or tissues. The capacity to quickly screen a large number of gene targets will be a key driver for many applications. Despite ongoing legal disputes over infringements of gene patents, this should result in more people having access to genetic testing and a successful conclusion for patients and their families.

Restraints/Challenges

High cost coupled with technology is acting as major restraint to the growth of the next generation sequencing in cancer diagnostic market in the above mentioned forecast period.  High costs connected with the installation of sequencing platforms, poor outsourced service efficiency, and limited availability of sequencing platforms in specific regional markets are all expected to restraint the overall development of the next generation sequencing in cancer diagnostic market.

This next generation sequencing (NGS) in cancer diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the next generation sequencing (NGS) in cancer diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Next Generation Sequencing (NGS) in Cancer Diagnostic Market

The COVID-19 epidemic had a huge influence on the world, causing economic collapse and death. It has resulted in a worldwide pandemic that is extremely transmissible. With the advancement of technology, next-generation sequencing is becoming increasingly important in a variety of fields. From manufacturing PPE kits to inventing test kits to detect the virus and vaccines to prevent transmission, a number of pharmaceutical businesses and agencies have contributed to reducing the infection's impact. To combat the virus, businesses have strengthened their R&D and production workforce due to the increasing benefit of determining and finding the genetic sequence of a virus, which helps scientists to comprehend the virus's entire mutation, the overall influence on the next generation sequencing industry and market is expected to be beneficial.

Recent Development

  • In January 2022, Agendia, Inc., a global pioneer in breast cancer precision medicine, announced a multi-year collaboration with Illumina to co-develop in vitro diagnostic (IVD) assays for oncology testing.
  • In October 2021, Roche introduced the AVENIO tumour tissue CGP kit to make tailored cancer research more accessible.

Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Scope

The next generation sequencing (NGS) in cancer diagnostic market is segmented on the basis of cancer type, product and service, technologies, workflow, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cancer Type

  • Lung
  • Breast
  •  Colorectal
  • Prostrate
  • Stomach
  •  Cervical
  •  Leukemia 
  • Others

 Product and Service

  • Kits
  • Software and Services and Instruments

 Technologies

  • Panels/Targeted Sequencing and Resequencing
  • Whole Exome Sequencing
  • Whole Genome Sequencing
  • RNA Sequencing
  • Other Sequencing Technologies

 Workflow

  • NGS Sequencing
  • NGS Data Analysis
  • NGS Pre-Sequencing

Application

  • Screening
  • Companion Diagnostics
  • Others

End User

  • Pathology Labs
  • Hospitals
  • Oncology Centers
  • Others

Distribution Channel

  • Direct Tender
  • Retail Sales

Next Generation Sequencing (NGS) in Cancer Diagnostic Market Regional Analysis/Insights

The next generation sequencing (NGS) in cancer diagnostic market is analysed and market size insights and trends are provided by country, cancer type, product and service, technologies, workflow, application, distribution channel and end-user as referenced above.

The countries covered in the next generation sequencing (NGS) in cancer diagnostic market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

China is dominating the market due to the technological advancements in molecular biology, it has enhanced the sequencing procedures, which is expected to enhance the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Next Generation Sequencing (NGS) in Cancer Diagnostic Market Share Analysis

The next generation sequencing (NGS) in cancer diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to next generation sequencing (NGS) in cancer diagnostic market.

Some of the major players operating in the next generation sequencing (NGS) in cancer diagnostic market are:

  • Illumina, Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Agilent Technologies Inc. (U.S.)
  • Myriad Genetics Inc. (U.S.)
  • BGI (China)
  • Perkin Elmer Inc. (U.S.)
  • Foundation Medicine Inc. (U.S.)
  • PacBio (U.S.)
  • Oxford Nanopore Technologies plc. (U.K.)
  • Paradigm Diagnostics Inc. (U.S.)
  • Caris Life Sciences (Japan)
  • Partek, Incorporated (U.S.)
  • Eurofins Scientific (Luxembourg)
  • Qiagen (Germany)


SKU-

Why Choose Us


Frequently Asked Questions

The next generation sequencing (NGS) in cancer diagnostic market value is expected USD 1825.29 million by 2029.
The Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market is to grow at a CAGR of 15.1% during the forecast by 2029.
On the basis of application, the Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market is segmented into Screening, Companion Diagnostics and Others.
The major players operating in the Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies Inc. (U.S.), Myriad Genetics Inc. (U.S.), BGI (China), Perkin Elmer Inc. (U.S.), Foundation Medicine Inc. (U.S.), PacBio (U.S.), Oxford Nanopore Technologies plc. (U.K.), Paradigm Diagnostics Inc. (U.S.), Caris Life Sciences (Japan), Partek, Incorporated (U.S.), Eurofins Scientific (Luxembourg), Qiagen (Germany).